Cara Therapeutics, Inc. (CARA)

8,48 -0,32 (-3,64%) Börsenschluss: 04:00PM EDT

Cara Therapeutics, Inc.

4 Stamford Plaza
9th Floor 107 Elm Street
Stamford, CT 06902
United States
203 406 3700
https://www.caratherapeutics.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 84

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Christopher A. Posner	Pres, CEO & Director	431,9k	N/A	1970
Dr. Derek T. Chalmers D.Sc., Ph.D.	Co-Founder & Sr. Advisor	580,93k	N/A	1964
Dr. Frédérique Menzaghi	Chief Scientific Officer and Sr. VP of R&D	826,94k	N/A	1966
Mr. Scott M. Terrillion	Chief Compliance Officer, Gen. Counsel & Corp. Sec.	689,63k	N/A	1963
Dr. Joana Goncalves	Chief Medical Officer	826,77k	N/A	1974
Mr. Richard Makara	VP, Head of Accounting, Controller, Principal Financial & Accounting Officer	N/A	N/A	1970
Dr. Iris Francesconi Ph.D.	Chief of Corp. Strategy & Investor Relations	N/A	N/A	N/A
Mr. Eric Vandal	Sr. VP of Commercial	N/A	N/A	N/A
Ms. Beth Weinberg	Sr. VP of Regulatory Affairs & QA	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2021 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. Its product candidate includes Oral KORSUVA (difelikefalin), which has completed Phase II clinical trial to treat pruritus atopic dermatitis and pruritus non-dialysis-dependent chronic kidney disease (NDD-CKD) associated pruritus; and in Phase II clinical trial to treat pruritus chronic liver disease (CLD) primary biliary cholangitis (PBC) and notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.

Corporate Governance

Cara Therapeutics, Inc.s ISS Governance QualityScore, Stand 31. Juli 2022, lautet 9. Die grundlegenden Scores sind Audit: 8, Vorstand: 9, Shareholderrechte: 8, Kompensation: 9.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.